Latest filingSep 18, 2026Most recent Form 4
DNTH
Dianthus Therapeutics, Inc. /DE/
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/19 to 09/19. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$235M6 sells
Net open-market-$235M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period10transactions
- S · Open-market sells · dominant6 · 60%
- M · Option exercise4 · 40%
Activity by reported role
A joint filing can contribute to multiple roles10transactions
- CAO · dominant7 · 70%
- Director3 · 30%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (1)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeCarr EdwardCommon Stock · Direct
5,301Sep 17, 2026
Read SimonCommon Stock · Direct
2,778Aug 19, 2026
Read SimonStock Option (Right to Buy) · Direct
19,445Aug 19, 2026
Carr EdwardStock Option (Right to Buy) · Direct
43,818Sep 17, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 19 → Sep 19
LessMore
Top insiders
By absolute net value across the selected period- CE-$1.7M
- RS-$275.5k
Recent filing activity
Most recent 10 transactions · color = transaction codeFiling detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
DNTH transaction history
Filters apply within this company and selected period by defaultLatest insider transactions
Form 4 filings from last month. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #225801 | DNTH | Carr Edward | CAO | exercise10b5-1 | 20.0k | $0 | M | 09/18 | 09/17 |
| #225800 | DNTH | Carr Edward | CAO | sale10b5-1 | 700 | -$7.30M | S | 09/18 | 09/17 |
| #225799 | DNTH | Carr Edward | CAO | sale10b5-1 | 1.10k | -$11.3M | S | 09/18 | 09/17 |
| #225798 | DNTH | Carr Edward | CAO | sale10b5-1 | 3.50k | -$35.8M | S | 09/18 | 09/17 |
| #225797 | DNTH | Carr Edward | CAO | sale10b5-1 | 6.77k | -$68.6M | S | 09/18 | 09/17 |
| #225796 | DNTH | Carr Edward | CAO | sale10b5-1 | 7.92k | -$79.6M | S | 09/18 | 09/17 |
| #225795 | DNTH | Carr Edward | CAO | exercise10b5-1 | 20.0k | $35.7M | M | 09/18 | 09/17 |
| #11867 | DNTH | Read Simon | DIR | exercise10b5-1 | 2.77k | $0 | M | 08/19 | 08/19 |
| #11866 | DNTH | Read Simon | DIR | sale10b5-1 | 2.77k | -$32.6M | S | 08/19 | 08/19 |
| #11865 | DNTH | Read Simon | DIR | exercise10b5-1 | 2.77k | $5.10M | M | 08/19 | 08/19 |
Dianthus Therapeutics, Inc. /DE/ Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Dianthus Therapeutics, Inc. /DE/?
CARR EDWARD, Read Simon.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Carr Edward reported a sale on Sep 17, 2026 valued at $7.30M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $2,354,199.60. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.